Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 3

2(25.0%)

N/A

1(12.5%)

8Total

Phase 2(5)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02215265Phase 3Active Not Recruiting

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

Role: lead

NCT01915693Phase 3Completed

ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study

Role: lead

NCT01537991Not ApplicableCompleted

ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial

Role: lead

NCT01972451Phase 2Completed

Feasibility of Reduction in Right Sided Bowel Cancer Through Contrast Enhanced Colonoscopy

Role: lead

NCT01788332Phase 2Unknown

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

Role: lead

NCT01032057Phase 2Completed

Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Role: lead

NCT02741856Phase 2Unknown

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation

Role: lead

NCT01843829Phase 2Unknown

A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer

Role: lead

All 8 trials loaded